Get started
BIOGAIA AB B O.N.BIOGAIA AB B O.N.BIOGAIA AB B O.N.

BIOGAIA AB B O.N.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BGLA chart


Full chart

BGLA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪928.70 M‬ EUR
Dividend yield (indicated)
6.85%
Price to earnings Ratio (TTM)
29.165
Basic EPS (TTM)
0.300 EUR
Net income (FY)
‪30.55 M‬ EUR
Revenue (FY)
‪123.69 M‬ EUR
Shares float
‪87.22 M‬
Beta (1Y)
0.33

Employees


Employees (FY)
225
Change (1Y)
+15 +7.14%
Revenue / Employee (1Y)
‪549.73 K‬ EUR
Net income / Employee (1Y)
‪135.77 K‬ EUR

About BIOGAIA AB SER. B


Sector
Health Technology
Industry
Pharmaceuticals: Other
CEO
Theresa Agnew
Website
biogaia.com
Headquarters
Stockholm
Founded
1990
ISIN
SE0017769995
FIGI
BBG000BFD5P0
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BGLA news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BGLA.

Frequently Asked Questions


The current price of BGLA is 9.175 EUR — it has decreased by −0.76% in the past 24 hours. Watch BIOGAIA AB B O.N. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange BIOGAIA AB B O.N. stocks are traded under the ticker BGLA.
BGLA stock has risen by 0.49% compared to the previous week, the month change is a −11.27% fall, over the last year BIOGAIA AB B O.N. has showed a −5.80% decrease.
We've gathered analysts' opinions on BIOGAIA AB B O.N. future price: according to them, BGLA price has a max estimate of 13.63 EUR and a min estimate of 9.99 EUR. Watch BGLA chart and read a more detailed BIOGAIA AB B O.N. stock forecast: see what analysts think of BIOGAIA AB B O.N. and suggest that you do with its stocks.
BGLA reached its all-time high on Feb 4, 2025 with the price of 12.000 EUR, and its all-time low was 6.645 EUR and was reached on Sep 29, 2022. View more price dynamics on BGLA chart.
See other stocks reaching their highest and lowest prices.
BGLA stock is 0.76% volatile and has beta coefficient of 0.33. Track BIOGAIA AB B O.N. stock price on the chart and check out the list of the most volatile stocks — is BIOGAIA AB B O.N. there?
Today BIOGAIA AB B O.N. has the market capitalization of ‪928.70 M‬, it has increased by 3.60% over the last week.
Yes, you can track BIOGAIA AB B O.N. financials in yearly and quarterly reports right on TradingView.
BIOGAIA AB B O.N. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
BGLA earnings for the last quarter are 0.070 EUR per share, whereas the estimation was 0.052 EUR resulting in a 35.29% surprise. The estimated earnings for the next quarter are 0.073 EUR per share. See more details about BIOGAIA AB B O.N. earnings.
BIOGAIA AB B O.N. revenue for the last quarter amounts to ‪31.72 M‬ EUR, despite the estimated figure of ‪29.08 M‬ EUR. In the next quarter, revenue is expected to reach ‪34.24 M‬ EUR.
BGLA net income for the last quarter is ‪7.12 M‬ EUR, while the quarter before that showed ‪3.22 M‬ EUR of net income which accounts for 121.09% change. Track more BIOGAIA AB B O.N. financial stats to get the full picture.
BIOGAIA AB B O.N. dividend yield was 1.74% in 2024, and payout ratio reached 56.09%. The year before the numbers were 1.88% and 52.52% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 25, 2025, the company has 225 employees. See our rating of the largest employees — is BIOGAIA AB B O.N. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGAIA AB B O.N. EBITDA is ‪42.26 M‬ EUR, and current EBITDA margin is 30.56%. See more stats in BIOGAIA AB B O.N. financial statements.
Like other stocks, BGLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGAIA AB B O.N. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGAIA AB B O.N. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGAIA AB B O.N. stock shows the strong sell signal. See more of BIOGAIA AB B O.N. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.